http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1509520-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07d5dcbb9f91a44c19e14317e706f590 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D455-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D455-06 |
| filingDate | 2003-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65d3841fcbdc96d9b201a00574da590d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16fc72f3094dd30b5d21fbb8d024804a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93d3e54fb75c7064a6a1743eef97fdb3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d3f25e4d356c2ac0a25d3cb8322cbd9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_870c8e9b807ff282193cc668180d732f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39f342104dfece897c5c9af2e8841ba1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b54a251607a1e2cff34318a44dcecde0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_643e91130cb230c9d0122b860f9a4bbc |
| publicationDate | 2005-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1509520-A1 |
| titleOfInvention | Use of benzo(c)quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction |
| abstract | Use of benzo(c)quinolizinium derivatives (I) in medicines for the treatment of pathological states due to constriction of smooth muscle cells, is new. Use of benzo(c)quinolizinium derivatives of formula (I) in medicines for the treatment of pathological states due to constriction of smooth muscle cells, is new. A = an aromatic or non-aromatic heterocycle, and if non-aromatic the nitrogen atom is attached to the 4a carbon atom by a double bond; R1-R5, R7-R10 = H, halo, 1-10 C alkyl, alkoxy, carbonyl, oxycarbonyl or ester (all optionally substituted by T), 5-10C aliphatic or aromatic ring (optionally substituted by T1), -OR1 or -NRbRc; or R1+R2, R2+R3, R3+R4, R4+R5, R7+R8, R8+R9, or R9+R10 = 5-10C aromatic or aliphatic ring optionally substituted by T1; or R3+R4 = indolyl substituted by Ra; T = halo, OH, primary, secondary or tertiary amino, or 5-10C aromatic or aliphatic rings that may themselves be optionally substituted; T1 = halo, OH, primary, secondary or tertiary amino; Ra-Rc = H, alkyl, carbonyl, oxycarbonyl, ester, or an aromatic or aliphatic ring; Y = -ORd, -NReRf; Rd-Rf = H, alkyl, alkoxy, carbonyl, oxycarbonyl, ester, or an aromatic or aliphatic ring; or Rd+R5, Rd+R7, Re+R5, Re+R7, Rf+R5, Rf+R7 = 5-10C aromatic or aliphatic ring optionally substituted by T1; X- = anion, e.g. halo or perchlorate. Independent claims are also included for new compounds (I; R5 = -COOR'). R' = 1-10C alkyl, especially ethyl. |
| priorityDate | 2002-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 153.